These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12116561)

  • 1. [When nucleoside analogs cannot be tolerated. HIV therapy with booster].
    MMW Fortschr Med; 2002 May; 144(19):64. PubMed ID: 12116561
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir and saquinavir combination: 12-week data at ICAAC.
    James JS
    AIDS Treat News; 1996 Oct; (No 256):3. PubMed ID: 11363880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
    Jahnke N; Seminari E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 1999; 4(3):151-6. PubMed ID: 12731754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 10. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 15. [Regimen simplification: lopinavir/ritonavir with or without efavirenz].
    Pacios E
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):553; author reply 553-4. PubMed ID: 19716632
    [No Abstract]   [Full Text] [Related]  

  • 16. Saquinavir plus ritonavir open-label study recruiting.
    AIDS Patient Care STDS; 1996 Oct; 10(5):308. PubMed ID: 11361524
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination study of Invirase and Norvir starting.
    AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.
    TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837
    [No Abstract]   [Full Text] [Related]  

  • 19. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination suppresses HIV RNA within the central nervous system.
    AIDS Patient Care STDS; 1998 Jan; 12(1):65. PubMed ID: 11361893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.